{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:12:27Z","timestamp":1791295947850,"version":"4.1.0"},"reference-count":59,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2013,8]]},"abstract":"ABSTRACT<\/jats:title>\n \n The SENTRY Antimicrobial Surveillance Program monitors global susceptibility and resistance rates of newer and established antifungal agents. We report the echinocandin and triazole antifungal susceptibility patterns for 3,418 contemporary clinical isolates of yeasts and molds. The isolates were obtained from 98 laboratories in 34 countries during 2010 and 2011. Yeasts not presumptively identified by CHROMagar, the trehalose test, or growth at 42\u00b0C and all molds were sequence identified using internal transcribed spacer (ITS) and 28S (yeasts) or ITS, translation elongation factor (TEF), and 28S (molds) genes. Susceptibility testing was performed against 7 antifungals (anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole) using CLSI methods. Rates of resistance to all agents were determined using the new CLSI clinical breakpoints and epidemiological cutoff value criteria, as appropriate. Sequencing of\n fks<\/jats:italic>\n hot spots was performed for echinocandin non-wild-type (WT) strains. Isolates included 3,107 from 21\n Candida<\/jats:named-content>\n spp., 146 from 9\n Aspergillus<\/jats:named-content>\n spp., 84 from\n Cryptococcus neoformans<\/jats:named-content>\n , 40 from 23 other mold species, and 41 from 9 other yeast species. Among\n Candida<\/jats:named-content>\n spp., resistance to the echinocandins was low (0.0 to 1.7%).\n Candida albicans<\/jats:named-content>\n and\n Candida glabrata<\/jats:named-content>\n that were resistant to anidulafungin, caspofungin, or micafungin were shown to have\n fks<\/jats:italic>\n mutations. Resistance to fluconazole was low among the isolates of\n C. albicans<\/jats:named-content>\n (0.4%),\n Candida tropicalis<\/jats:named-content>\n (1.3%), and\n Candida parapsilosis<\/jats:named-content>\n (2.1%); however, 8.8% of\n C. glabrata<\/jats:named-content>\n isolates were resistant to fluconazole. Among echinocandin-resistant\n C. glabrata<\/jats:named-content>\n isolates from 2011, 38% were fluconazole resistant. Voriconazole was active against all\n Candida<\/jats:named-content>\n spp. except\n C. glabrata<\/jats:named-content>\n (10.5% non-WT), whereas posaconazole showed decreased activity against\n C. albicans<\/jats:named-content>\n (4.4%) and\n Candida krusei<\/jats:named-content>\n (15.2% non-WT). All agents except for the echinocandins were active against\n C. neoformans<\/jats:named-content>\n , and the triazoles were active against other yeasts (MIC\n 90<\/jats:sub>\n , 2 \u03bcg\/ml). The echinocandins and triazoles were active against\n Aspergillus<\/jats:named-content>\n spp. (MIC\n 90<\/jats:sub>\n \/minimum effective concentration [MEC\n 90<\/jats:sub>\n ] range, 0.015 to 2 \u03bcg\/ml), but the echinocandins were not active against other molds (MEC\n 90<\/jats:sub>\n range, 4 to >16 \u03bcg\/ml). Overall, echinocandin and triazole resistance rates were low; however, the fluconazole and echinocandin coresistance among\n C. glabrata<\/jats:named-content>\n strains warrants continued close surveillance.\n <\/jats:p>","DOI":"10.1128\/jcm.00308-13","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T00:48:07Z","timestamp":1369874887000},"page":"2571-2581","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":207,"title":["Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance"],"prefix":"10.1128","volume":"51","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn A.","family":"Messer","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah N.","family":"Woosley","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.06.012"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis697"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00039-07"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/504491"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01685-08"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01686-12"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks019"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-012-9551-x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.10.003"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02061-06"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00937-12"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2010.08.013","article-title":"Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)","volume":"69","author":"Pfaller MA","year":"2011","unstructured":"PfallerMA CastanheiraM MesserSA MoetGJ JonesRN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45\u201350.","journal-title":"Diagn. Microbiol. Infect. Dis"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06112-11"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01398-10"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.643-658.2001"},{"key":"e_1_3_3_18_2","volume-title":"CLSI document M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts\u2014third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_19_2","volume-title":"CLSI M27-S3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; 3rd informational supplement. CLSI M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_20_2","volume-title":"CLSI document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi\u2014second eddition. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01935.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.06.004"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr511"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.2.415"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2010.01988.x"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.529-535.2006"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm212"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-010-0134-z"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2010.09.002"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.03.002"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.01.004"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0b013e32833e84d2"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01711-09"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00412-07"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01624-08"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01590-09"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00536-10"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh504"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06252-11"},{"key":"e_1_3_3_41_2","first-page":"1762","volume-title":"Manual of clinical microbiology","author":"Hazen KC","year":"2007","unstructured":"HazenKC HowellSA. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p 1762\u20131788. In MurrayPR BaronEJ JorgensenJH LandryML PfallerMA (ed), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.","edition":"9"},{"key":"e_1_3_3_42_2","volume-title":"Medically important fungi: a guide to identification","author":"Larone DH","year":"2002","unstructured":"LaroneDH. 2002. Medically important fungi: a guide to identification, 4th ed. ASM Press, Washington, DC.","edition":"4"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.3.693-699.2006"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00156-08"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01952-07"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06369-11"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.508469"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110226"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq279"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq450"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00854-09"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.8.3623-3626.2003"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/500212"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn022"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1086\/374557"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1086\/503425"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1086\/340522"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1086\/314042"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02390-09"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00308-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00308-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T06:46:39Z","timestamp":1646462799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00308-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1128\/JCM.00308-13"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00308-13","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"2013-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}